| Catalog No. | HB185026 |
|---|
| Description | Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225Ac]Ac-lintuzumab clinical trials were discussed in detail in reference. Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia). |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | IgG1-kappa |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3 |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P20138 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | 225Ac-lintuzumab, HuM195, SGN-33, SMARTM195, HuM195, 166089-32-3 |
|---|
| Background | Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia.
• Gene therapy for Alzheimer's disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation., PMID:32803224
• Hypoxia/ischemia impairs CD33 (Siglec-3)/TREM2 signaling: Potential role in Alzheimer's pathogenesis., PMID:34530055
• Reporter cell assay for human CD33 validated by specific antibodies and human iPSC-derived microglia., PMID:34188106
• CD33 isoforms in microglia and Alzheimer's disease: Friend and foe., PMID:35940942
• Siglecs in Brain Function and Neurological Disorders., PMID:31546700
• SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection., PMID:34060491
• Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window., PMID:38561023
• CD33 as a leukocyte-associated marker expressed on human spermatozoa., PMID:37081561
• Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer's disease., PMID:35452678
• Deletion of Alzheimer's disease-associated CD33 results in an inflammatory human microglia phenotype., PMID:33539598
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
